64,986 Shares in Hologic, Inc. (HOLX) Purchased by USA Financial Portformulas Corp

USA Financial Portformulas Corp purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 64,986 shares of the medical equipment provider’s stock, valued at approximately $2,949,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hall Laurie J Trustee raised its stake in shares of Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 225 shares in the last quarter. Commonwealth Bank of Australia raised its stake in shares of Hologic by 31.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 600 shares in the last quarter. National Asset Management Inc. purchased a new stake in shares of Hologic during the 2nd quarter worth about $203,000. Miles Capital Inc. purchased a new stake in shares of Hologic during the 1st quarter worth about $206,000. Finally, Beck Mack & Oliver LLC purchased a new stake in shares of Hologic during the 2nd quarter worth about $209,000. 96.38% of the stock is owned by institutional investors.

Hologic, Inc. (HOLX) traded down 0.7445% during mid-day trading on Monday, reaching $36.0099. The company’s stock had a trading volume of 1,740,694 shares. The company has a 50 day moving average of $37.64 and a 200-day moving average of $41.89. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80. The stock has a market cap of $10.10 billion, a PE ratio of 13.4115 and a beta of 0.91.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The firm had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.51 earnings per share. Equities analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “64,986 Shares in Hologic, Inc. (HOLX) Purchased by USA Financial Portformulas Corp” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/16/64986-shares-in-hologic-inc-holx-purchased-by-usa-financial-portformulas-corp.html.

In other Hologic news, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now owns 23,810 shares of the company’s stock, valued at $955,257.20. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lawrence M. Levy sold 7,138 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $37.38, for a total value of $266,818.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,775 shares of company stock worth $1,175,662. Company insiders own 0.79% of the company’s stock.

A number of equities research analysts have recently weighed in on HOLX shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $49.00 price target on shares of Hologic in a research note on Wednesday, June 28th. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a research note on Friday, July 14th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 price target on shares of Hologic in a research note on Friday, July 14th. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $53.00 price target (up from $50.00) on shares of Hologic in a research note on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $47.77.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hall Laurie J Trustee raised its stake in shares of Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 225 shares in the last quarter. Commonwealth Bank of Australia raised its stake in shares of Hologic by 31.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 600 shares in the last quarter. National Asset Management Inc. purchased a new stake in shares of Hologic during the 2nd quarter worth about $203,000. Miles Capital Inc. purchased a new stake in shares of Hologic during the 1st quarter worth about $206,000. Finally, Beck Mack & Oliver LLC purchased a new stake in shares of Hologic during the 2nd quarter worth about $209,000. 96.38% of the stock is owned by institutional investors.

Hologic, Inc. (HOLX) traded down 0.7445% during mid-day trading on Monday, reaching $36.0099. The company’s stock had a trading volume of 1,740,694 shares. The company has a 50 day moving average of $37.64 and a 200-day moving average of $41.89. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80. The stock has a market cap of $10.10 billion, a PE ratio of 13.4115 and a beta of 0.91.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The firm had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.51 earnings per share. Equities analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “64,986 Shares in Hologic, Inc. (HOLX) Purchased by USA Financial Portformulas Corp” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/16/64986-shares-in-hologic-inc-holx-purchased-by-usa-financial-portformulas-corp.html.

In other Hologic news, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now owns 23,810 shares of the company’s stock, valued at $955,257.20. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lawrence M. Levy sold 7,138 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $37.38, for a total value of $266,818.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,775 shares of company stock worth $1,175,662. Company insiders own 0.79% of the company’s stock.

A number of equities research analysts have recently weighed in on HOLX shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $49.00 price target on shares of Hologic in a research note on Wednesday, June 28th. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a research note on Friday, July 14th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 price target on shares of Hologic in a research note on Friday, July 14th. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $53.00 price target (up from $50.00) on shares of Hologic in a research note on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $47.77.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply